DelveInsight’s, “Central Serous Chorioretinopathy – Pipeline Insight, 2020,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Central Serous Chorioretinopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
• Global coverage
Central Serous Chorioretinopathy Understanding
Central Serous Chorioretinopathy: Overview
Central serous Chorioretinopathy is a condition in which fluid accumulates under the retina, causing a serous (fluid-filled) detachment and vision loss. Central serous Chorioretinopathy most often occurs in young and middle-aged adults. For unknown reasons, men develop this condition more commonly than women. Vision loss is usually temporary but sometimes can become chronic or recur.
The symptoms of Central Serous Chorioretinopathy include:
• Blurry central vision
• Blurred vision in one eye
• Brown or dull tinge to vision
A complete dilated eye examination of both eyes to obtain the image of the retina. Retinal photographs may be taken to document the appearance of disease. Optical coherence tomography (OCT) is a retinal scan that is very helpful in diagnosing Central Serous Chorioretinopathy. Fluorescein angiography is a test in which a dye is injected into a patient’s arm vein and pictures are taken of each eye to detect characteristic leakage of the dye beneath the patient’s retina.
Several therapies have been used to treat chronic CSC, including thermal laser treatments, oral medications, and eye injections. A “cold laser,” called photodynamic therapy, is also effective and often used to focally treat the source of fluid leakage under the retina in chronic CSC. With photodynamic therapy, a drug called verteporfin is injected into the arm, where it travels to the eye. The verteporfin is activated by shining a special cold laser on the source of leakage in chronic CSC. It may also prevent future recurrences in some eyes. Early detection of CSC is very helpful, and most eyes with CSC can be treated successfully to avoid permanent vision loss.
Central Serous Chorioretinopathy Emerging Drugs Chapters
This segment of the Central Serous Chorioretinopathy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Central Serous Chorioretinopathy Emerging Drugs
• Aflibercept: Bayer
Aflibercept is a drug that is a placenta growth factor inhibitors and vascular endothelial growth factor A inhibitors. It is was originally developed by Regeneron Pharmaceuticals and later licensed to Bayer and Sanofi. It is currently in Phase 2 of clinical study.
• Mifepristone: Corcept Therapeutics
Mifepristone is a Phase 2 glucocorticoid receptor antagoists and progestrone receptor anatagonists. It was originally developed by Roussel Ucalf at Standford University and later licensed to Corcept Therapeutics, Danco Laboratories, and HRA Pharma. It is presently being developed by Corcept Therapeutics.
Further product details are provided in the report……..
Central Serous Chorioretinopathy: Therapeutic Assessment
This segment of the report provides insights about the different Central Serous Chorioretinopathy drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Central Serous Chorioretinopathy
There are approx. 3+ key companies which are developing the therapies for Central Serous Chorioretinopathy. The companies which have their Central Serous Chorioretinopathy drug candidates in the most advanced stage, i.e. phase III include, Bayer.
DelveInsight’s report covers around 3+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Gastroparesis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Molecule Type
Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Small molecule
• Gene therapy
• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Central Serous Chorioretinopathy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Central Serous Chorioretinopathy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Central Serous Chorioretinopathy drugs.
• The companies and academics are working to assess challenges and seek opportunities that could influence Central Serous Chorioretinopathy R&D. The therapies under development are focused on novel approaches to treat/improve Central Serous Chorioretinopathy.
Central Serous Chorioretinopathy Report Insights
• Central Serous Chorioretinopathy Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs
Central Serous Chorioretinopathy Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Central Serous Chorioretinopathy drugs?
• How many Central Serous Chorioretinopathy drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Central Serous Chorioretinopathy?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Central Serous Chorioretinopathy therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Central Serous Chorioretinopathy and their status?
• What are the key designations that have been granted to the emerging drugs?
• Corcept Therapeutics
• Targetd Therapy Technlogies
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook